阿莫西林剂量与疗程对儿童社区获得性肺炎需抗生素再治疗的影响:CAP-IT随机临床试验
这项多中心2×2析因非劣效性试验纳入824名6月龄及以上临床诊断社区获得性肺炎的儿童,比较低剂量(35-50 mg/kg/d)与高剂量(70-90 mg/kg/d)阿莫西林及3天与7天疗程。主要结局28天内需抗生素再治疗率低剂量组12.6% vs 高剂量组12.4%(差值0.2%,单侧95%CI -∞至4.0%),3天组12.5% vs 7天组12.5%(差值0.1%,单侧95%CI -∞至3.9%),均达非劣效。
要点
- 低剂量阿莫西林(35-50 mg/kg/d)在28天内需抗生素再治疗方面非劣效于高剂量(70-90 mg/kg/d)。
- 3天疗程非劣效于7天疗程,主要结局发生率均为12.5%。
- 3天组 vs 7天组咳嗽持续时间中位12天 vs 10天(HR 1.2,95%CI 1.0-1.4,P=.04),因咳嗽睡眠受扰中位4天 vs 4天(HR 1.2,95%CI 1.0-1.4,P=.03)。
核心结论
- 在急诊或病房(48小时内)出院的社区获得性肺炎患儿中,低剂量口服阿莫西林在需抗生素再治疗方面非劣效于高剂量,3天疗程非劣效于7天疗程。
- 解读结果时需考虑疾病严重程度、治疗场所、既往抗生素使用及非劣效界值的可接受性。
研究设计与样本
- 多中心、随机、2×2析因非劣效性试验,纳入824名6月龄及以上临床诊断社区获得性肺炎的儿童。
- 患儿于2017年2月至2019年4月期间从英国28家医院及爱尔兰1家医院的急诊和病房出院时入组,末次访视于2019年5月21日。
- 随机1:1分配至低剂量阿莫西林(35-50 mg/kg/d,n=410)或高剂量(70-90 mg/kg/d,n=404),以及短疗程(3天,n=413)或长疗程(7天,n=401)。
- 814名参与者至少接受1剂试验药物(中位[IQR]年龄2.5岁[1.6-2.7];男性421名[52%],女性393名[48%]),789名(97%)有主要结局数据。
主要发现
- 主要结局(随机后28天内因呼吸道感染临床需要抗生素再治疗):低剂量组12.6% vs 高剂量组12.4%(差值0.2%,单侧95%CI -∞至4.0%),3天组12.5% vs 7天组12.5%(差值0.1%,单侧95%CI -∞至3.9%),均达非劣效,剂量与疗程间无显著交互作用(P=.63)。
- 14个预设次要终点中仅2项有显著差异:3天组 vs 7天组咳嗽持续时间中位12天 vs 10天(HR 1.2,95%CI 1.0-1.4,P=.04);因咳嗽睡眠受扰中位4天 vs 4天(HR 1.2,95%CI 1.0-1.4,P=.03)。
- 严重社区获得性肺炎亚组:主要终点低剂量组17.3% vs 高剂量组13.5%(差值3.8%,单侧95%CI -∞至10%,交互作用P=.18);3天组16.0% vs 7天组14.8%(差值1.2%,单侧95%CI -∞至7.4%,交互作用P=.73)。
关键数值与推荐
- 非劣效界值为8%。
- 低剂量阿莫西林35-50 mg/kg/d,高剂量70-90 mg/kg/d,均为口服。
- 疗程比较为3天 vs 7天。
局限性
- 作者指出解读结果时需考虑疾病严重程度、治疗场所、既往抗生素使用及非劣效界值的可接受性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The optimal dose and duration of oral amoxicillin for children with community-acquired pneumonia (CAP) are unclear. OBJECTIVE: To determine whether lower-dose amoxicillin is noninferior to higher dose and whether 3-day treatment is noninferior to 7 days. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, 2 × 2 factorial noninferiority trial enrolling 824 children, aged 6 months and older, with clinically diagnosed CAP, treated with amoxicillin on discharge from emergency departments and inpatient wards of 28 hospitals in the UK and 1 in Ireland between February 2017 and April 2019, with last trial visit on May 21, 2019. INTERVENTIONS: Children were randomized 1:1 to receive oral amoxicillin at a lower dose (35-50 mg/kg/d; n = 410) or higher dose (70-90 mg/kg/d; n = 404), for a shorter duration (3 days; n = 413) or a longer duration (7 days; n = 401). MAIN OUTCOMES AND MEASURES: The primary outcome was clinically indicated antibiotic re-treatment for respiratory infection within 28 days after randomization. The noninferiority margin was 8%. Secondary outcomes included severity/duration of 9 parent-reported CAP symptoms, 3 antibiotic-related adverse events, and phenotypic resistance in colonizing Streptococcus pneumoniae isolates. RESULTS: Of 824 participants randomized into 1 of the 4 groups, 814 received at least 1 dose of trial medication (median [IQR] age, 2.5 years [1.6-2.7]; 421 [52%] males and 393 [48%] females), and the primary outcome was available for 789 (97%). For lower vs higher dose, the primary outcome occurred in 12.6% with lower dose vs 12.4% with higher dose (difference, 0.2% [1-sided 95% CI -∞ to 4.0%]), and in 12.5% with 3-day treatment vs 12.5% with 7-day treatment (difference, 0.1% [1-sided 95% CI -∞ to 3.9]). Both groups demonstrated noninferiority with no significant interaction between dose and duration (P = .63). Of the 14 prespecified secondary end points, the only significant differences were 3-day vs 7-day treatment for cough duration (median 12 days vs 10 days; hazard ratio [HR], 1.2 [95% CI, 1.0 to 1.4]; P = .04) and sleep disturbed by cough (median, 4 days vs 4 days; HR, 1.2 [95% CI, 1.0 to 1.4]; P = .03). Among the subgroup of children with severe CAP, the primary end point occurred in 17.3% of lower-dose recipients vs 13.5% of higher-dose recipients (difference, 3.8% [1-sided 95% CI, -∞ to10%]; P value for interaction = .18) and in 16.0% with 3-day treatment vs 14.8% with 7-day treatment (difference, 1.2% [1-sided 95% CI, -∞ to 7.4%]; P value for interaction = .73). CONCLUSIONS AND RELEVANCE: Among children with CAP discharged from an emergency department or hospital ward (within 48 hours), lower-dose outpatient oral amoxicillin was noninferior to higher dose, and 3-day duration was noninferior to 7 days, with regard to need for antibiotic re-treatment. However, disease severity, treatment setting, prior antibiotics received, and acceptability of the noninferiority margin require consideration when interpreting the findings. TRIAL REGISTRATION: ISRCTN Identifier: ISRCTN76888927.
引用
- Bielicki JA, Stöhr W, Barratt S, et al. Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial. JAMA. 2021. PMID: 34726708. doi:10.1001/jama.2021.17843
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。